Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2017/09/009618
CTRI/2017/09/009618
Completed
Phase 2

An open label, interventional, multi-center, prospective clinical study to Evaluation of Efficacy and Safety of JP-16 Capsules in Patients Suffering from Mild to Moderate Sexual Dysfunction - NI

Chatarubhuj Pharmaceutical Co0 sites40 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: null- erectile dysfunction

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: null- erectile dysfunction
Sponsor
Chatarubhuj Pharmaceutical Co
Enrollment
40
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
August 25, 2016
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Chatarubhuj Pharmaceutical Co

Eligibility Criteria

Inclusion Criteria

  • •1\. Subjects who have scored 22 to 25 on the Erectile Function (EF) domain of the International Index of Erectile Function (IIEF) at screening.
  • •2\. Subject without any organic cause of Sexual Dysfunction.
  • •3\. Subjects should be in an active stable sexual relationship for the duration of study

Exclusion Criteria

  • •1\. Subjects with major illnesses and sexual dysfunction due to anatomical, surgical or pharmacological causes
  • •2\. Subjects with total erectile failure or any other sexual disorder
  • •3\. Subjects with history of disorders that may cause priapism
  • •4\. Subjects with history of major psychiatric disorder
  • •5\. Subjects with history of central nervous system disorders such as stroke, transient ischemic attacks or spinal cord injury or pelvic surgery
  • •6\. Patients with preexisting systemic disease necessitating long\-term medications, genetic and endocrinal disorders

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Clinical study on IMPERIM® Capsule in erectile dysfunction.Health Condition 1: N529- Male erectile dysfunction, unspecified
CTRI/2019/09/021217Dr Bioveda Lab
Completed
Phase 2
Clinical study on Ayuvigo Forte Capsule in erectile dysfunctio
CTRI/2017/08/009425Welex Laboratories Pvt Ltd38
Completed
Phase 2
Clinical study on Ayuvigo Forte Capsules in patients with less sperm countHealth Condition 1: N461- Oligospermia
CTRI/2017/06/008799Welex Laboratories Pvt Ltd30
Active, not recruiting
Not Applicable
One cohort Study To Assess the duration of the improvement following NOVA22007 Treatment Discontinuation in Improved Patients With Severe Dry Eye Disease.
EUCTR2012-002066-12-ATOVAGALI Pharma S.A.S130
Active, not recruiting
Not Applicable
One cohort Study To Assess the duration of the improvement following NOVA22007 Treatment Discontinuation in Improved Patients With Severe Dry Eye Disease.Severe Dry Eye DiseaseMedDRA version: 14.1Level: LLTClassification code 10023350Term: Keratoconjunctivitis siccaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10013778Term: Dry eyesSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10013777Term: Dry eye syndromeSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: PTClassification code 10013774Term: Dry eyeSystem Organ Class: 10015919 - Eye disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]
EUCTR2012-002066-12-GBOVAGALI Pharma S.A.S130